In tRCCs, the overexpression of PD-L1 on RNA-Seq is consistent with the findings from a large study performed on the immunohistochemistry in which tRCCs showed PD-L1 overexpression in both tumor-infiltrating mononuclear cells (90%) and tumoral cells (30%) [46,47]. The gene discussed is CD274; the disease is neoplasm.